Manufacturing and delivery pipeline of genetically modified T-cell therapies. Manufacturing and delivery pipeline of genetically modified T-cell therapies.

Slides:

Advertisements

Similar presentations

I.1 ii.2 iii.3 iv.4 1+1=. i.1 ii.2 iii.3 iv.4 1+1=

Advertisements

I.1 ii.2 iii.3 iv.4 1+1=. i.1 ii.2 iii.3 iv.4 1+1=

Safe and Effective Re-Induction of Complete Remissions in Adults with Relapsed B-ALL Using 19-28z CAR CD19-Targeted T Cell Therapy Davila ML et al. Proc.

Kochenderfer JN et al. Proc ASH 2013;Abstract 168.

Genetic Engineering. Genetic Engineering- manipulating genes for practical purposes Examples 1. Medicine Many medicines, such as the ones used to treat.

Introducing Apceden™.

KEY CONCEPT Genetics provides a basis for new medical treatments.

Optimization of T cell expansion in a perfusion bioreactor

T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia by Michael Kalos, Bruce.

1 Steven A. Feldman, Ph.D. Surgery Branch, NCI MEASUREMENT CHALLENGES FOR CAR-T BIOMANUFACTURING January 29, 2016 Adoptive Cell Therapy for the Treatment.

Evaluation of CD19 specific Chimeric Antigen Receptor T cells (CAR19 T-cells) as an optimal bridge to allogeneic transplantation. Phase I trial for patients.

Immunotherapy with CD19 CAR redirected T-cells for high risk, relapsed paediatric CD19+ acute lymphoblastic leukaemia (ALL) and other haematological malignancies.

The Principles of Engineering Immune Cells to Treat Cancer

Socializing Individualized T-Cell Cancer Immunotherapy

chimeric antigen receptor T-cell therapy for ALL

Immunotherapy of hepatocellular carcinoma

Learning Goals. Harnessing the Immune System: Mechanism of Action of Immunotherapies in B-Cell Malignancies.

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Man's Best Friend: Utilizing Naturally Occurring Tumors in Dogs to Improve Chimeric Antigen Receptor T-cell Therapy for Human Cancers Melinda Mata, Stephen.

Research Techniques Made Simple: CAR T-Cell Therapy

Figure 1 Chimeric antigen receptor (CAR) structures

KEY CONCEPT Genetics provides a basis for new medical treatments.

Antibody-modified T cells: CARs take the front seat for hematologic malignancies by Marcela V. Maus, Stephan A. Grupp, David L. Porter, and Carl H. June.

Engineering regulatory T cells against factor VIII inhibitors

CAR T cell therapy—principle and clinical trial overview

Cell to Cell Communication via Steroids & Hormones

Overview. Maximizing the Safety of CAR T-Cell Therapy: Prevention, Early Recognition, and Management.

CAR T cell therapy—principle and clinical trial overview

Figure 1 CAR-T-cell design

T cell receptor Vβ (TCR-Vβ) expression in a drug-specific T cell line (TCL) and specificity assay of a TCL of patient P1. T cell receptor Vβ (TCR-Vβ) expression.

KEY CONCEPT Genetics provides a basis for new medical treatments.

DNA CLONING IN CANCER TREATMENT : GENE INFUSION (CAR-T Therapy)

KEY CONCEPT Genetics provides a basis for new medical treatments.

Figure 2 Approaches to improve CAR-T-cell therapy

Figure 2 Site of action of checkpoint inhibitors and agonists being

Figure 2 Logistical requirements for autologous

Nat. Rev. Endocrinol. doi: /nrendo

The Other Face of Chimeric Antigen Receptors

Volume 3, Issue 5, Pages (May 2003)

Global Manufacturing of CAR T Cell Therapy

Research Techniques Made Simple: CAR T-Cell Therapy

The Principles of Engineering Immune Cells to Treat Cancer

The Pharmacology of T Cell Therapies

Figure 1 Mechanisms of action of immunotherapy modalities

KEY CONCEPT Genetics provides a basis for new medical treatments.

Volume 21, Issue 4, Pages (April 2013)

Nat. Rev. Clin. Oncol. doi: /nrclinonc

KEY CONCEPT Genetics provides a basis for new medical treatments.

Management of Cytokine Release Syndrome (CRS) in Patients Undergoing Chimeric Antigen Receptor Modified (CAR) T-Cell Therapy Following Autologous Stem.

Thunder and Lightning: Immunotherapy and Oncolytic Viruses Collide

TP53 western blot of primary cultured tail cells from both wild-type (WT) and Tp53Δ11/Δ11 (−/−) rats. TP53 western blot of primary cultured tail cells.

Patient and control ONS cells had very large differences in gene expression. Patient and control ONS cells had very large differences in gene expression.

Genetic Engineering AQA: 3.4, EdExcel: 7.4 OCR:

The Drosophila pipeline for modeling human disease.

SLE: the many players involved in systemic autoimmunity and tissue destruction. SLE: the many players involved in systemic autoimmunity and tissue destruction.

Cells of the innate and adaptive immune systems.

Genetically modified TCRs for cancer immunotherapy.

CD8+ T-cell subsets. CD8+ T-cell subsets. There are a number of different CD8+ T-cell subsets. Naïve, T stem cell (TSCM) and T central memory (TCM) cells.

Engineering of Chimeric Antigen Receptor therapy.

2DG downregulates the expression of HIF-1α, PDK1 and c-Myc in NB xenograft. 2DG downregulates the expression of HIF-1α, PDK1 and c-Myc in NB xenograft.

Z-stack compressions showing triple labelling of different cell types in the gills of bowfin with antibodies for serotonin (5-HT, green) and HNK-1 (magenta),

Cell-Intrinsic Barriers of T Cell-Based Immunotherapy

Releasing the Brakes on Cancer Immunotherapy

Overview of iPSC applications in biomedical research.

HFHC/STZ guinea pigs develop insulin-independent diabetes that is responsive to oral antihyperglycemic therapy. HFHC/STZ guinea pigs develop insulin-independent.

Peroxisome speeds were slower in patient and control cells.

KEY CONCEPT Genetics provides a basis for new medical treatments.

Relapses were identified by the sudden and marked increase in the number of hospital procedures (y axis), accompanied by a change in treatment associated.

Kaplan–Meier curves of relapse-free survival of the CAR-T cohort (left) and the HCT cohort (right) of 8 CAR-T patients and 12 HCT patients whose preceding.

Strategies for adoptive immunotherapy of HCMV

Presentation transcript:

Manufacturing and delivery pipeline of genetically modified T-cell therapies. Manufacturing and delivery pipeline of genetically modified T-cell therapies. (i) T cells are harvested from a patient and sent to a good manufacturing practices (GMP) manufacturing facility, which might not be local to the treating hospital. Cells that pass acceptance criteria are genetically engineered (ii) with either a new T cell receptor (TCR) or a receptor based on a recognition sequence of an antibody [chimeric antigen receptor (CAR)], combined with T-cell co-stimulatory sequences. After a brief period of in vitro expansion and passing of product-specific release criteria (iii), the T-cell product must be returned to the correct patient (iv). The patient can undergo conditioning regimens prior to infusion of the genetically modified T-cell product (v). The complexity of this multi-step process in the manufacture and delivery of T-cell immunotherapies poses several economic and regulatory issues, which represent a challenge for the improvement and accessibility of such therapies. PBMC, peripheral blood mononuclear cell. Michaela Sharpe, and Natalie Mount Dis. Model. Mech. 2015;8:337-350 © 2015. Published by The Company of Biologists Ltd